Loading…
Microbot Medical Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in MBOT.
▼ -82.4% over 5Y.
today you would have $181.37▼ -81.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.00 | $1.12 | $1.64 | $3.01 | $7.50 | $6.89 | $10.17 | $1.72 | $15.30 | $91.50 | $680.40 | $1,522.80 | $1,992.60 | $2,640.60 | $1,328.40 | $17,496.00 | $20,412.00 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PARKPark Dental Partners, Inc. | $20.85 | — | 3.3x | — | -24.16% | $99.15M |
| SEERSeer, Inc. | $1.80 | — | 0.4x | — | -26.45% | $99.67M |
| YARWYarrow Bioscience, Inc. | $37.00 | — | — | — | — | $98.78M |
| VRCAVerrica Pharmaceuticals Inc. | $5.69 |
Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices such as microcatheters within the body's vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts
Company description provided by Yahoo Finance.
| P/E | — | — | — | — | — | — | — | — | — | — | 15.3x | 1134.0x | — | — | — | — | — | — |
| P/S | 68.3x | — | — | — | — | — | — | — | — | — | — | 404.3x | — | 68.3x | 46.3x | 15.6x | 96.4x | — |
| P/B | 4.5x | 1.7x | 11.0x | 5.2x | 3.4x | 3.7x | 2.0x | 2.3x | 5.6x | 4.3x | 98.0x | — | 76.0x | 4.6x | 4.5x | 1.8x | 8.9x | — |
| EPS | -$0.29 | -$0.73 | -$1.05 | -$1.81 | -$1.59 | -$1.29 | -$1.70 | -$2.41 | -$2.76 | $6.00 | $0.60 | -$858.60 | -$988.20 | -$1,603.80 | -$2,430.00 | -$3,321.00 | -$4,131.00 |
| Profit margin | -1925.89% | — | — | — | — | — | — | — | — | — | — | -787.94% | — | -2649.30% | -2082.76% | -1747.28% | -1769.03% | -2722.05% |
| ROE | -178.73% | -16.95% | -324.16% | -238.61% | -180.66% | -78.67% | -37.72% | -22.98% | -545.86% | -75.95% | -569.75% | — | -3820.45% | -176.81% | -203.73% | -198.87% | -163.07% | -88.63% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 22.7x |
| — |
| — |
| $97.75M |
| CGTXCognition Therapeutics Inc | $1.02 | — | 2.9x | — | -83.76% | $97M |
| LNSRLENSAR, Inc. | $8.30 | 41.5x | 6.8x | — | 357.30% | $101.97M |